Loading...
•
Dec 31, 2024
Amneal Q4 2024 Earnings Report
Amneal reported strong revenue growth across all segments, reducing net losses and improving financial stability.
Key Takeaways
Amneal Pharmaceuticals posted Q4 2024 revenue of $731 million, an 18% increase from Q4 2023, driven by growth in all business segments. The company reported a net loss of $31 million, significantly lower than the $99 million loss in the prior-year quarter. Adjusted EBITDA reached $155 million, supported by strong product launches and operational efficiencies. Adjusted diluted EPS was $0.12 compared to $0.14 in Q4 2023.
Revenue increased 18% year-over-year, reaching $731 million in Q4 2024.
Net loss reduced to $31 million, improving from $99 million in Q4 2023.
Adjusted EBITDA rose to $155 million, reflecting strong sales and cost management.
Announced financial guidance for 2025 with expected revenue of $3.0 to $3.1 billion.
Amneal
Amneal
Amneal Revenue by Segment
Revenue by Segment
Affordable Medicines Revenue
CapyFin.comSpecialty Revenue
CapyFin.comAvKARE Revenue
CapyFin.com Forward Guidance
Amneal expects revenue growth in 2025, driven by expansion in Specialty, Biosimilars, and GLP-1 therapies, along with new product launches.
Positive Outlook
- Projected 2025 revenue between $3.0 billion and $3.1 billion.
- Expected Adjusted EBITDA of $650 million to $675 million.
- Continued strong growth in Specialty and Affordable Medicines segments.
- Expanding presence in high-growth areas such as GLP-1 therapies.
- Reduction of net leverage to below 4x ahead of schedule.
Challenges Ahead
- Ongoing net losses despite revenue growth.
- Higher interest expenses impacting profitability.
- Potential pricing pressures in the pharmaceutical industry.
- Increased R&D and commercial expenses for future product launches.
- Regulatory risks associated with biosimilars and new therapies.
Revenue & Expenses
Visualization of income flow from segment revenue to net income